Fingolimod after natalizumab and the risk of short-term relapse.

ABSTRACT:

Objective

To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse on fingolimod.

Methods

Data were obtained from the MSBase Registry. Relapse rates (RRs) for each patient group were compared using adjusted negative binomial regression. Survival analyses coupled with adjusted Cox regression were used to model predictors of time to first relapse on fingolimod.

Results

A total of 536 patients (natalizumab-fingolimod [n = 89]; IFN-β/GA-fingolimod [n = 350]; naive-fingolimod [n = 97]) were followed up for a median 10 months. In the natalizumab-fingoli

SUBMITTER: Jokubaitis VG 

PROVIDER: S-EPMC4001200 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature